



(12) Translation of
European patent specification

(11) NO/EP 2888259 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/551 (2006.01)
A61P 1/04 (2006.01)
A61P 25/16 (2006.01)
A61P 25/28 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2018.08.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.03.07
(86)	European Application Nr.	13783671.4
(86)	European Filing Date	2013.08.21
(87)	The European Application's Publication Date	2015.07.01
(30)	Priority	2012.08.23, GB, 201215033
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA
(73)	Proprietor	Novartis AG, Lichtstrasse 35, 4056 Basel, CH-Sveits
(72)	Inventor	BEHNKE, Dirk, Novartis Pharma AGWerk KlybeckPostfach, CH-4002 Basel, CH-Sveits CARCACHE, David, Novartis Pharma AGPostfach, CH-4002 Basel, CH-Sveits ERTL, Peter, Novartis Pharma AGPostfach, CH-4002 Basel, CH-Sveits KOLLER, Manuel, Novartis Pharma AGPostfach, CH-4002 Basel, CH-Sveits ORAIN, David, Novartis Pharma AGPostfach, CH-4002 Basel, CH-Sveits
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE
(56)	References Cited:	WO-A2-2005/123703, WO-A2-2004/087048

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formelen I



5 eller et salt derav, hvori

A er et fusjonert fem- til sju-leddet monosyklisk ringsystem som kan være aromatisk, mettet eller umettet ikke-aromatisk og som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel;

R₁ er halogen; cyano; nitro; hydroksy; amino; -C(O)H; -C(O)NH₂; -X₁-R₅; eller -X₂-B₂;

X₁ er valgt fra binding; karbonyl; oksygen; svovel; -S(O)-; -S(O)₂-; amino, som kan være substituert med C₁₋₄alkyl; -NH-C(O)-; -C(O)-NH-; -C(O)-O-; -O-C(O)-; -NH-S(O)₂-; -S(O)₂-NH-; og -NHC(O)NH-;

R₅ er C₁₋₆alkyl; C₁₋₆halogenalkyl; C₁₋₆cyanoalkyl; C₁₋₆karboksyalkyl; C₁₋₆hydroksyalkyl; C₁₋₄alkoksy-C₁₋₆alkyl; C₁₋₄alkoksy-C₁₋₄alkoksy-C₁₋₆alkyl; C₁₋₄alkylkarbonyl-C₁₋₆alkyl; C₁₋₄alkoksykarbonyl-C₁₋₆alkyl; C₁₋₄alkylkarbonyloksy-C₁₋₆alkyl; C₁₋₆aminoalkyl; C₁₋₄alkylamino-C₁₋₆alkyl; di(C₁₋₄alkyl)amino-C₁₋₆alkyl; aminokarbonyl-C₁₋₆alkyl; C₁₋₄alkylaminokarbonyl-C₁₋₆alkyl; di(C₁₋₄alkyl)aminokarbonyl-C₁₋₆alkyl; C₁₋₄alkylkarbonylamino-C₁₋₆alkyl; C₁₋₄alkylaminosulfonyl-C₁₋₆alkyl; di(C₁₋₄alkyl)aminosulfonyl-C₁₋₆alkyl; C₂₋₆alkenyl; C₂₋₆halogenalkenyl; C₂₋₆alkinyl; C₂₋₆halogenalkinyl;

X₂ er binding eller C₁₋₃alkylen, hvori ett karbonatom av C₁₋₃alkylenet kan være erstattet av en gruppe valgt fra karbonyl; oksygen; svovel; -S(O)-; -S(O)₂-; amino, som kan være substituert med C₁₋₄alkyl; -NH-C(O)-; -C(O)-NH-; -C(O)-O-; -O-C(O)-; -NH-S(O)₂-; -S(O)₂-NH-; og -NHC(O)NH-;

B₂ er et tre- til sju-leddet monosyklisk ringsystem som kan være aromatisk, mettet eller umettet ikke-aromatisk og som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₆;

hver R₆ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy; eller to R₆ på det samme ringatomet sammen er okso;

m er 0, 1, 2, 3 eller 4;

hver R₂ er uavhengig halogen, cyano, hydroksy, amino, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄hydroksyalkyl; C₁₋₄aminoalkyl; C₁₋₄alkylamino-C₁₋₄alkyl; di-(C₁₋₄alkyl)amino-C₁₋₄alkyl; C₁₋₄alkoksy-C₁₋₄alkyl; C₂₋₄alkenyl; C₂₋₄halogenalkenyl; C₂₋₄alkinyl; C₂₋₄halogenalkinyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy; C₁₋₄alkyl-amino; di-(C₁₋₄alkyl)amino eller C₃₋₆sykloalkyl, hvori ett karbonatom av C₃₋₆sykloalkylet kan være erstattet av et oksygenatom og hvori C₃₋₆sykloalkylet kan være bundet direkte til ringsystemet eller via et C₁₋₂alkylen eller et oksygen;

n er 0, 1, 2, 3 eller 4;

hver R₃ er uavhengig halogen, cyano, hydroksy, amino, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄hydroksyalkyl; C₁₋₄aminoalkyl; C₁₋₄alkylamino-C₁₋₄alkyl; di-(C₁₋₄alkyl)amino-C₁₋₄alkyl; C₁₋₄alkoksy-C₁₋₄alkyl; C₂₋₄alkenyl; C₂₋₄halogenalkenyl; C₂₋₄alkinyl; C₂₋₄halogenalkinyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy; C₁₋₄alkyl-amino; di-(C₁₋₄alkyl)amino eller C₃₋₆sykloalkyl, hvori ett karbonatom av C₃₋₆sykloalkylet kan være erstattet av et oksygenatom og hvori C₃₋₆sykloalkylet kan være bundet direkte til ringsystemet eller via et C₁₋₂alkylen eller et oksygen;

R₄ er hydrogen, halogen, cyano, hydroksy, amino, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄hydroksyalkyl; C₁₋₄aminoalkyl; C₁₋₄alkylamino-C₁₋₄alkyl; di-(C₁₋₄alkyl)amino-C₁₋₄alkyl; C₁₋₄alkoksy-C₁₋₄alkyl; C₂₋₄alkenyl; C₂₋₄halogenalkenyl; C₂₋₄alkinyl; C₂₋₄halogenalkinyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy; C₁₋₄alkyl-amino; di-(C₁₋₄alkyl)amino eller C₃₋₆sykloalkyl, hvori ett karbonatom av C₃₋₆sykloalkylet kan være erstattet av et oksygenatom og hvori C₃₋₆sykloalkylet kan være bundet direkte til ringsystemet eller via et C₁₋₂alkylen eller et oksygen;

B₁ er et fem- til seks-leddet aromatisk ringsystem, som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₇;

hver R₇ er uavhengig

halogen, cyano, hydroksy, amino,

C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄hydroksyalkyl; C₁₋₄aminoalkyl; C₁₋₄alkylamino-C₁₋₄alkyl; di-(C₁₋₄alkyl)amino-C₁₋₄alkyl; C₁₋₄alkoksy-C₁₋₄alkyl;

C₂₋₄alkenyl; C₂₋₄halogenalkenyl; C₂₋₄alkinyl; C₂₋₄halogenalkinyl;

C₁₋₄alkoksy; C₁₋₄alkoksy-C₁₋₄alkoksy C₁₋₄halogenalkoksy;

C₁₋₄alkyl-amino; di-(C₁₋₄alkyl)amino;

C₁₋₄alkoksykarbonyl;

eller et tre- til sju-leddet monosyklisk ringsystem som kan være aromatisk, mettet eller umettet ikke-aromatisk og som kan inneholde fra 1 til 4

heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur

kan være substituert én gang eller mer enn én gang ved R₈;
 hver R₈ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy; eller to R₈ på det samme ringatomet sammen er okso;

5 eller to R₇ ved tilstøtende ringatomer atomer sammen med ringatomene danner et fusjonert fem- til sju-leddet monosyklisk umettet ikke-aromatisk ringsystem som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₉;

10 hver R₉ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy; eller to R₉ på det samme ringatomet sammen er okso.

2. Forbindelse med formel I ifølge krav 1, eller et salt derav, hvori A er fenyl.

15

3. Forbindelse med formel I ifølge et hvilket som helst av kravene 1 eller 2, eller et salt derav, hvori R₁ er -X₂-B₂, hvori X₂ er binding; B₂ er C₃₋₆sykloalkyl som kan være substituert én gang eller mer enn én gang ved R₆;

20 eller B₂ er et fem- til seks-leddet aromatisk ringsystem som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₆; hver R₆ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy.

25 **4.** Forbindelse med formel I ifølge et hvilket som helst av kravene 1-3, eller et salt derav, hvori

m er 0, 1 eller 2;

hver R₂ er uavhengig halogen, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy eller C₃₋₆sykloalkyl;

30 n er 0; og

R₄ er hydrogen.

5. Forbindelse med formel I ifølge et hvilket som helst av kravene 1-4, eller et salt derav, hvori B₁ er et fem- til seks-leddet aromatisk ringsystem, som

35 inneholder fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₇; og hvori hver R₇ er uavhengig halogen, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋

4alkoksy-C₁₋₄alkyl, C₁₋₄alkoksy, C₁₋₄alkoksy-C₁₋₄alkoksy eller C₃₋₆sykloalkyl.

6. Forbindelse med formel I ifølge krav 1, eller et salt derav, hvori

A er fenyl;

5 R₁ er -X₂-B₂, hvori X₂ er binding;

B₂ er C₃₋₆sykloalkyl som kan være substituert én gang eller mer enn én gang ved R₆;

eller B₂ er et fem- til seks-leddet aromatisk ringsystem som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₆;

10 hver R₆ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy;

m er 0, 1 eller 2;

hver R₂ er uavhengig halogen, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy eller C₃₋₆sykloalkyl;

15 n er 0, 1 eller 2;

hver R₃ er uavhengig halogen, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy eller C₃₋₆sykloalkyl;

R₄ er hydrogen, halogen, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄alkoksy; C₁₋₄halogenalkoksy eller C₃₋₆sykloalkyl;

20 B₁ er et fem- til seks-leddet aromatisk ringsystem, som inneholder fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₇;

og hvori hver R₇ er uavhengig halogen, C₁₋₄alkyl; C₁₋₄halogenalkyl; C₁₋₄alkoksy-C₁₋₄alkyl, C₁₋₄alkoksy, C₁₋₄alkoksy-C₁₋₄alkoksy eller C₃₋₆sykloalkyl.

25

7. Forbindelse med formel I ifølge krav 1, hvori forbindelsen er valgt fra gruppen bestående av

9-metoksy-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

30 9-klor-2-(tiofen-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

9-klor-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

2-(tiofen-2-yl)-9-(trifluormetyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

35 9-metoksy-2-(tiofen-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 9-klor-2-(2-metoksypyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(5-metylfuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 9-metoksy-2-(2-metoksypyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(6-metoksypyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(2-etylpyridin-4-yl)-9-metoksy-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(1-metyl-1H-pyrazol-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(3-(2-metoksyetoksy)fenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 10-klor-9-metoksy-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 11-klor-9-metoksy-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 2-(3-etoksyfenyl)-9-metoksy-7-metyl-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(3-(trifluormetyl)fenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(4-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 9-metoksy-2-(5-metoksy-2-metylfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-fluor-2-(tiofen-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-brom-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 2-(2-(dimetylamino)pyridin-4-yl)-9-metoksy-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(2-metoksypyridin-4-yl)-9-morfolino-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(5-metylfuran-2-yl)-9-morfolino-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 2-(1-metyl-1H-pyrazol-3-yl)-9-morfolino-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 2-(1-metyl-1H-pyrazol-4-yl)-9-morfolino-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-(2-hydroksypropan-2-yl)-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 5 9-(2-hydroksypropan-2-yl)-2-(1-metyl-1H-pyrazol-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(furan-2-yl)-9-(pyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-brom-2-(tiofen-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 10 9-jod-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-jod-2-(1-metyl-1H-pyrazol-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-jod-2-(1-metyl-1H-pyrazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 15 9-jod-2-(2-metoksypyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(furan-3-yl)-9-jod-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-jod-2-(1-isopropyl-1H-pyrazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 20 9-jod-2-(1-metyl-1H-imidazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-metoksy-2-(4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-etyl-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 25 on;
 9-etynyl-2-(tiofen-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 5-okso-2-(tiofen-2-yl)-4,5,7,8-tetrahydro-[1,4]diazepino[7,1-a]isokinolin-9-karbonitril;
 2-(1-metyl-1H-pyrazol-3-yl)-5-okso-4,5,7,8-tetrahydro-[1,4]diazepino[7,-
 30 a]isokinolin-9-karbonitril;
 2-(3-metoksyfenyl)-9-morfolino-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(1-isopropyl-1H-pyrazol-4-yl)-9-(1H-pyrazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 35 9-((dimetylamino)metyl)-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 9-((2-metoksyetoksy)metyl)-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-(hydroksymetyl)-2-(1-metyl-1H-pyrazol-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 9-(hydroksymetyl)-2-(1-metyl-1H-pyrazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-(1-metoksyetyl)-2-(1-metyl-1H-pyrazol-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 9-acetyl-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-metoksyfenyl)-9-fenyl-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(2-metoksypyridin-4-yl)-9-(pyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 2-(furan-3-yl)-9-(pyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(2-metoksypyridin-4-yl)-9-(pyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-(6-fluorpyridin-3-yl)-2-(2-metoksypyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 9-(3-fluorpyridin-4-yl)-2-(2-metoksypyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(1-metyl-1H-imidazol-4-yl)-9-(pyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 2-(1-metyl-1H-pyrazol-3-yl)-9-(2-metylpyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-metoksyfenyl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on,
- (R)-2-(3-metoksyfenyl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 (S)-2-(3-metoksyfenyl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-metoksy-2-(6-okso-1,6-dihydropyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 9,10-dimetoksy-2-(3-metoksyfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 9-metoksy-2-(2-okso-1,2-dihydropyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(4-isopropyl-1H-imidazol-1-yl)-9-metoksy-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 5 9-klor-2-(4-metyl-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 9-jod-2-(4-(trifluormetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 10 1-(9-jod-5-okso-4,5,7,8-tetrahydro-[1,4]diazepino[7,1-a]isokinolin-2-yl)-1H-imidazol-4-karbonitril;
 2-(4-(hydroksymetyl)-1H-imidazol-1-yl)-9-jod-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 metyl-1-(9-jod-5-okso-4,5,7,8-tetrahydro-[1,4]diazepino[7,1-a]isokinolin-2-yl)-1H-imidazol-4-karboksylat;
 15 2-(2,4-dimetyl-1H-imidazol-1-yl)-9-jod-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 etyl-1-(9-jod-5-okso-4,5,7,8-tetrahydro-[1,4]diazepino[7,1-a]isokinolin-2-yl)-1H-imidazol-4-karboksylat;
 20 2-(4-syklobutyl-1H-imidazol-1-yl)-9-(1H-pyrazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(4-syklobutyl-1H-imidazol-1-yl)-9-morfolino-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(4-(metoksymetyl)-1H-imidazol-1-yl)-9-(tiazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 25 2-(4-isopropyl-1H-imidazol-1-yl)-9-(1-metyl-1H-pyrazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(4-isopropyl-1H-imidazol-1-yl)-9-(1-metyl-1H-imidazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 30 2-(4-etyl-1H-imidazol-1-yl)-9-(oksazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(4-etyl-1H-imidazol-1-yl)-9-(furan-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 2-(4-(2-metoksyetyl)-1H-imidazol-1-yl)-9-(tiazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
 35 2-(4-(metoksymetyl)-1H-imidazol-1-yl)-9-(5-metyltiazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 2-(4-metyl-1H-imidazol-1-yl)-9-(pyrimidin-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-metyl-1H-imidazol-1-yl)-9-(pyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 2-(4-metyl-1H-imidazol-1-yl)-9-(pyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-(6-fluorpyridin-3-yl)-2-(4-metyl-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(4-metyl-1H-imidazol-1-yl)-9-(tiazol-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-klor-1H-imidazol-1-yl)-9-(5-fluorpyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-(6-fluorpyridin-3-yl)-2-(4-(2-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 2-(4-(metoksymetyl)-1H-imidazol-1-yl)-9-vinyl-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-etyl-1H-imidazol-1-yl)-9-(4-fluorfenyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(4-metyloksazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(5-metyloksazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-(oksazol-2-yl)-1H-imidazol-1-yl)-9-propyl-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 9-etyl-2-(4-isopropyl-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-metyl-1H-imidazol-1-yl)-9-propyl-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklobutyl-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 9-syklobutyl-2-(3-metyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(3-(metoksymetyl)-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 4-(6-fluorpyridin-3-yl)-11-(4-isopropyl-1H-imidazol-1-yl)-5,6-dihydro-[1,4]diazepino[1,7-h][1,7]naftyridin-8(9H)-on;

- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(6-fluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2-fluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklobutyl-1H-imidazol-1-yl)-9-(2-fluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2,6-difluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(isoksazol-5-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-(metoksymetyl)-1H-imidazol-1-yl)-9-(tiazol-4-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 2-(3-etyl-1H-1,2,4-triazol-1-yl)-9-(6-fluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(6-fluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(3-metylisotiazol-5-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(oksazol-2-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-etylnyl-1H-imidazol-1-yl)-9-(tiazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-
a]isokinolin-5(4H)-on;
- 25 9-(2-fluorpyridin-3-yl)-2-(4-(oksazol-2-yl)-1H-imidazol-1-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-1-metyl-9-(3-metylisoksazol-5-yl)-7,8-
dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2-metyloksazol-4-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 [1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(oksazol-5-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(6-fluorpyridin-3-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a][2,6]naftyridin-5(4H)-on;
- 35 2-(4-etyl-1H-imidazol-1-yl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-
[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- (R)-2-(4-etyl-1H-imidazol-1-yl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (S)-2-(4-etyl-1H-imidazol-1-yl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 2-(4-(tert-butyl)-1H-imidazol-1-yl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (R)-2-(4-(tert-butyl)-1H-imidazol-1-yl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (S)-2-(4-(tert-butyl)-1H-imidazol-1-yl)-9-(tetrahydrofuran-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(4-etyl-1H-imidazol-1-yl)-9-(1-fluorsyklobutyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-etyl-1H-imidazol-1-yl)-9-(3-fluoroksetan-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 2-(4-etyl-1H-imidazol-1-yl)-9-(1-hydroksyetyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (R)-2-(4-etyl-1H-imidazol-1-yl)-9-(1-hydroksyetyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (S)-2-(4-etyl-1H-imidazol-1-yl)-9-(1-hydroksyetyl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 9-acetyl-2-(4-metyl-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-acetyl-2-(4-syklobutyl-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-9-(prop-1-en-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (R)-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-9-(prop-1-en-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (S)-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-9-(prop-1-en-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 9-(syklopent-1-en-1-yl)-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-(metoksymetyl)-1H-imidazol-1-yl)-9-(prop-1-en-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 9-syklopropyl-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;


- (S)-9-syklopropyl-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (R)-9-syklopropyl-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 2-(4-syklobutyl-1H-imidazol-1-yl)-9-propionyl-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on; og
- 9-(tert-butyl)-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(3-fluorpyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(3-fluorpyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(tiazol-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2-metyltiazol-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(pyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(tiazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 2-(4-(2-metoksyetyl)-1H-imidazol-1-yl)-9-(tiazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-(etoksymetyl)-1H-imidazol-1-yl)-9-(4-metyltiazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 2-(4-(etoksymetyl)-1H-imidazol-1-yl)-9-(tiazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(4-fluorpyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-10-fluor-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 2-(4-metyl-1H-imidazol-1-yl)-9-(2-metyloksazol-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(3-(trifluormetyl)-1H-pyrazol-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(6-hydroksypyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(6-metoksypyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(1H-pyrazol-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2-fluorpyrimidin-5-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2-fluorpyridin-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(3-syklobutyl-1H-1,2,4-triazol-1-yl)-9-(6-fluorpyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-12-fluor-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- (R)-9-syklopropyl-12-fluor-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 9-syklopropyl-11-fluor-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(difluormetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(fluormetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 (R)-9-syklopropyl-10-fluor-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10-fluor-9-(6-fluorpyridin-3-yl)-2-(3-metyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 9-syklopropyl-10-fluor-2-(3-(metoksymetyl)-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-10-fluor-9-(2-fluorpyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10-fluor-9-(2-fluorpyridin-3-yl)-2-(3-metyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 30 10-fluor-9-(2-fluorpyridin-3-yl)-2-(4-metyl-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-(6-fluorpyridin-3-yl)-2-(4-(1-metoksysyklopropyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 2-(4-metyl-1H-imidazol-1-yl)-9-(pyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 9-(6-fluorpyridin-3-yl)-2-(4-(3-hydroksyoksetan-3-yl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(2-metyloksazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 2-(4-syklobutyl-1H-imidazol-1-yl)-9-(2-metyloksazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-metyl-1H-imidazol-1-yl)-9-(2-metyloksazol-4-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-syklopropyl-1H-imidazol-1-yl)-7,8-dihydro-
- 10 [1,4]diazepino[7,1-a][2,6]naftyridin-5(4H)-on;
- 9-syklopropyl-2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a][2,6]naftyridin-5(4H)-on;
- (R)-9-syklopropyl-2-(4-(1-metoksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a][2,6]naftyridin-5(4H)-on;
- 15 9-syklopropyl-2-(4-(difluormetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a][2,6]naftyridin-5(4H)-on;
- 9-syklopropyl-2-(4-(oksazol-5-yl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(isoksazol-5-yl)-1H-imidazol-1-yl)-7,8-dihydro-
- 20 [1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-metoksy-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 9-syklopropyl-2-(4-(trifluormetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(pyridin-4-yl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(hydroksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-
- 30 [1,4]diazepino[7,1-a]isokinolin-5(4H)-on ;
- 9-syklopropyl-2-(4-(1-hydroksysyklopropyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-(2-hydroksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 35 9-syklopropyl-2-(4-(1-hydroksyetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;

- 9-syklopropyl-2-(4-(syklopropyl(hydroksy)metyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-syklopropyl-2-(4-((trifluormetoksy)metyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 5 metyl-2-(4-syklopropyl-1H-imidazol-1-yl)-5-okso-4,5,7,8-tetrahydro-[1,4]diazepino[7,1-a]isokinolin-9-karboksylat;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(5-fluorpyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(6-fluorpyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 10 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(4-fluorpyridin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(3-syklopropyl-1H-1,2,4-triazol-1-yl)-9-(5-fluorpyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 15 9-(5-fluorpyrazin-2-yl)-2-(3-metyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(2H-1,2,3-triazol-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(5-fluorpyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 20 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(6-fluorpyrazin-2-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 9-isopropoksy-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on;
- 25 eller salter av disse forbindelsene.


8. Forbindelse ifølge krav 1 som er 9-syklopropyl-10-fluor-2-(4-(metoksymetyl)-1H-imidazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on, som har den følgende formelen



30

eller salt derav.


9. Forbindelse ifølge krav 1 som er 2-(4-syklopropyl-1H-imidazol-1-yl)-9-(6-fluorpyridin-3-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on, som har den følgende formelen



;

5 eller salt derav.

10. Forbindelse ifølge krav 1 som er 9-(5-fluorpyrazin-2-yl)-2-(3-metyl-1H-1,2,4-triazol-1-yl)-7,8-dihydro-[1,4]diazepino[7,1-a]isokinolin-5(4H)-on, som har den følgende formelen



;

10 eller salt derav.


11. Farmasøytisk sammensetning omfattende en terapeutisk effektiv mengde av en forbindelse ifølge et hvilket som helst av kravene 1 til 10, eller et salt derav, og én eller flere farmasøytisk akseptable bærere.

12. Kombinasjon omfattende en terapeutisk effektiv mengde av forbindelsen ifølge et hvilket som helst av kravene 1 til 10, eller et salt derav, og én eller flere terapeutisk aktive midler.

13. Forbindelse ifølge et hvilket som helst av kravene 1 til 10, eller et farmasøytisk akseptabelt salt derav, for anvendelse som et legemiddel.


14. Forbindelse ifølge et hvilket som helst av kravene 1 til 10, eller et salt derav, til anvendelse i forebyggingen, behandlingen eller forsinkelsen av progresjonen av lidelser valgt fra PD-LID, fragilt X-syndrom, obsessiv kompulsiv lidelse og substansrelaterte lidelser.

15. Forbindelse med formelen III




eller et salt derav, hvori A, R₂, m, R₃, n og R₄ er som definert ifølge krav 1, og X_A er halogen; eller

forbindelse med formel V




eller et salt derav, hvori A, R₂, m, R₃, n og R₄ er som definert ifølge krav 1, og X_A er halogen; eller

forbindelse med formel VI




eller et salt derav, hvori A, R₂, m, R₃, n og R₄ er som definert ifølge krav 1, og X_A er halogen; eller

forbindelse med formel VIII



eller et salt derav, hvori A, R₂, m, R₃, n og R₄ er som definert ifølge krav 1, og R₁ er C₁₋₆alkyl; C₁₋₆halogenalkyl; C₁₋₆cyanoalkyl; C₁₋₆karboksyalkyl; C₁₋₆hydroksyalkyl; C₁₋₄alkoksy-C₁₋₆alkyl; C₁₋₄alkoksy-C₁₋₄alkoksy-C₁₋₆alkyl; C₁₋₄alkylkarbonyl-C₁₋₆alkyl; C₁₋₄alkoksykarbonyl-C₁₋₆alkyl; C₁₋₄alkylkarbonyloksy-C₁₋₆alkyl; C₁₋₆aminoalkyl; C₁₋₄alkylamino-C₁₋₆alkyl; di(C₁₋₄alkyl)amino-C₁₋₆alkyl; aminokarbonyl-C₁₋₆alkyl; C₁₋₄alkylaminokarbonyl-C₁₋₆alkyl; di(C₁₋₄alkyl)aminokarbonyl-C₁₋₆alkyl; C₁₋₄alkylkarbonylamino-C₁₋₆alkyl; C₁₋₄alkylaminosulfonyl-C₁₋₆alkyl; di(C₁₋₄alkyl)aminosulfonyl-C₁₋₆alkyl; C₂₋₆alkenyl; C₂₋₆halogenalkenyl; C₂₋₆alkinyl; C₂₋₆halogenalkinyl; eller et tre- til sju-leddet monosyklisk ringsystem som kan være aromatisk, mettet eller umettet ikke-aromatisk og som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet er bundet via et karbonatom, og hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₆; hver R₆ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy; eller to R₆ på det samme ringatomet sammen er okso; eller forbindelse med formel IX



eller et salt derav, hvori A, R₂, m, R₃, n og R₄ er som definert ifølge krav 1, og R₁ er C₁₋₆alkyl; C₁₋₆halogenalkyl; C₁₋₆cyanoalkyl; C₁₋₆karboksyalkyl; C₁₋₆hydroksyalkyl; C₁₋₄alkoksy-C₁₋₆alkyl; C₁₋₄alkoksy-C₁₋₄alkoksy-C₁₋₆alkyl; C₁₋₄alkylkarbonyl-C₁₋₆alkyl; C₁₋₄alkoksykarbonyl-C₁₋₆alkyl; C₁₋₄alkylkarbonyloksy-C₁₋₆alkyl; C₁₋₆aminoalkyl; C₁₋₄alkylamino-C₁₋₆alkyl; di(C₁₋₄alkyl)amino-C₁₋₆alkyl; aminokarbonyl-C₁₋₆alkyl; C₁₋₄alkylaminokarbonyl-C₁₋₆alkyl; di(C₁₋₄alkyl)aminokarbonyl-C₁₋₆alkyl; C₁₋₄alkylkarbonylamino-C₁₋₆alkyl; C₁₋₄alkylaminosulfonyl-C₁₋₆alkyl; di(C₁₋₄alkyl)aminosulfonyl-C₁₋₆alkyl; C₂₋₆alkenyl;

- 5 C₂₋₆halogenalkenyl; C₂₋₆alkinyl; C₂₋₆halogenalkinyl; eller et tre- til sju-leddet monosyklisk ringsystem som kan være aromatisk, mettet eller umettet ikke-aromatisk og som kan inneholde fra 1 til 4 heteroatomer valgt fra nitrogen, oksygen og svovel, hvori ringsystemet er bundet via et karbonatom, og hvori ringsystemet i sin tur kan være substituert én gang eller mer enn én gang ved R₆; hver R₆ er uavhengig halogen, hydroksy, cyano, C₁₋₄alkyl, C₁₋₄halogenalkyl, C₁₋₄alkoksy eller C₁₋₄halogenalkoksy; eller to R₆ på det samme ringatomet sammen er okso.